25th Anniversary Top Portlet

Beyond Surgery: The Evolving Landscape of Adjuvant Therapy in Kidney Cancer

The FDA requires additional confirmatory evidence to progress the application for TLX101-CDx in this glioma indication.

Manojkumar Bupathi, MD, MS;Manojkumar Bupathi, MD, MS

Nogapendekin Alfa Inbakicept Elicits Promising Efficacy in Bladder Carcinoma

Oncology Decoded hosts discuss adjuvant therapy in kidney cancer, including research, treatment strategies, and management of recurrence.

Tony Berberabe, MPH

Elucidating Non-Invasive Radiosurgery Advancements in CNS Tumors

Nogapendekin alfa inbakicept plus BCG led to a CR rate of 71%, with 60% of responders maintaining their response for at least 12 months, in patients with bladder carcinoma in situ.

A dedicated, well-trained, and expert staff at the Ivy Brain Tumor Center enables the facility to be at the forefront of cutting-edge radiosurgery treatment.

William R. Kennedy, MD

April 28th 2025

Perioperative Pembrolizumab Enhances Survival in Locally Advanced HNSCC

A dedicated, well-trained, and expert staff at the Ivy Brain Tumor Center enables the facility to be at the forefront of cutting-edge radiosurgery treatment.

Event-free survival events were observed in 37.5% of patients taking pembrolizumab vs 45.3% without among patients with resectable locally advanced HNSCC.

Ashley Chan

79 Case Series of Pathologic Upgrade After Reconstructive Breast Surgery

Event-free survival events were observed in 37.5% of patients with resectable locally advanced HNSCC who took pembrolizumab vs 45.3% in those who did not.

Rebecca Martin;Angelis Vazquez-Perez;Alice Trye;Nilofer Sidhu;Lucy M. De La Cruz;Jennifer Son

FDA Sends CRL for PET Imaging Agent in Progressive/Recurrent Glioma

Related Content

Tim Cortese;Russ Conroy

Beyond Surgery: The Evolving Landscape of Adjuvant Therapy in Kidney Cancer

The FDA requires additional confirmatory evidence to progress the application for TLX101-CDx in this glioma indication.

Manojkumar Bupathi, MD, MS;Manojkumar Bupathi, MD, MS

Nogapendekin Alfa Inbakicept Elicits Promising Efficacy in Bladder Carcinoma

Oncology Decoded hosts discuss adjuvant therapy in kidney cancer, including research, treatment strategies, and management of recurrence.

Tony Berberabe, MPH

Elucidating Non-Invasive Radiosurgery Advancements in CNS Tumors

Nogapendekin alfa inbakicept plus BCG led to a CR rate of 71%, with 60% of responders maintaining their response for at least 12 months, in patients with bladder carcinoma in situ.

William R. Kennedy, MD

April 28th 2025

Perioperative Pembrolizumab Enhances Survival in Locally Advanced HNSCC

A dedicated, well-trained, and expert staff at the Ivy Brain Tumor Center enables the facility to be at the forefront of cutting-edge radiosurgery treatment.

Ashley Chan

79 Case Series of Pathologic Upgrade After Reconstructive Breast Surgery

Event-free survival events were observed in 37.5% of patients with resectable locally advanced HNSCC who took pembrolizumab vs 45.3% in those who did not.

Rebecca Martin;Angelis Vazquez-Perez;Alice Trye;Nilofer Sidhu;Lucy M. De La Cruz;Jennifer Son